AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

AstraZeneca's experimental Covid-19 antibody drug cocktail succeeded in reducing severe disease or death in non-hospitalized patients in a late-stage study, the British drugmaker said on Monday.

The drug, called AZD7442, reduced the risk of developing severe Covid-19 or death by 50% in patients who had been symptomatic for seven days or less, meeting the main goal of the trial.

"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca.

The company will discuss the data with health authorities, it added, without elaborating.

AstraZeneca is also developing the drug cocktail as a therapy to protect people who do not have a strong enough immune response to Covid-19 vaccines. It requested emergency approval from U.S. regulators for its use as a prevention drug last week.

CNBC Health & Science

Read CNBC's latest global coverage of the Covid pandemic:

'We will comply': Spirit Airlines CEO prepares staff for federal Covid vaccine mandate  

Covid cases dip below 100,000 a day in U.S. as nation faces colder weather and more closed-in spaces  

Nordic countries are restricting the use of Moderna's Covid vaccine. Here's why 

As C-suite Covid fears stay high, big companies 'totally support' Biden vaccine mandate: CNBC Survey

Fired for refusing a Covid vaccine? You likely can't get unemployment benefits

Source: Read Full Article